Safety and danger of biologic treatments in psoriasis
in context of cutaneous T-cell lymphoma (CTCL)

Karol Kołkowski; Małgorzata Sokołowska-Wojdyło

doi:10.5114/ada.2021.107553

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2021
vol. 38

Send email

Copy url:

abstract:

Review paper

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)

Karol Kołkowski

¹

,

Małgorzata Sokołowska-Wojdyło

²

Dermatological Students Scientific Association, Department of Dermatology, Venerology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

Adv Dermatol Allergol 2021; XXXVIII (6): 953–960

DOI: https://doi.org/10.5114/ada.2021.107553

Online publish date: 2021/10/25

View full text Get citation

Microenvironment has a significant impact on the pathogenesis of cutaneous T-cell lymphoma (CTCL), especially in the context of new emerging biologic therapies. Our aim was to review the literature on interleukins 12, 17, 23 and tumour necrosis factor-a in mycosis fungoides in order to clarify the safety of using biologics in the treatment of psoriasis. Our analysis suggests that these drugs may have an impact on the progression of CTCL. Concluding, in case of uncertain psoriatic lesions, a biopsy followed by pathologic examination should exclude the possibility of co-existence of a primary cutaneous lymphoma before administration of therapies affecting cytokine profiles.

keywords:

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)

Karol Kołkowski 1 , Małgorzata Sokołowska-Wojdyło 2

cutaneous T-cell lymphoma, mycosis fungoides, biologic treatment, psoriasis, interleukin-12, interleukin-17, tumour necrosis factor-a

Karol Kołkowski

¹

,

Małgorzata Sokołowska-Wojdyło

²